CANbridge In-Licenses China Rights to Oral Mucositis Treatment

CANbridge Life Sciences of Beijing in-licensed China rights to a treatment for oral mucositis from EUSA Pharma, a subsidiary of Jazz Pharma. The product, Caphosol®, is an oral rinse that treats oral mucositis, a condition caused by radiation or high-dose chemotherapy. Because Caphosol is a rinse, it is classified as a medical device, though the solution is not harmful if swallowed. Caphosol is approved for use in the US and Europe. More details.... Stock Symbol: (NSDQ: JAZZ) Share this with colleagues: // //